COMPASS Pathways plc (CMPS) は上場企業です ヘルスケア セクターの Medical - Care Facilities 業界で事業展開. 本社所在地は London, イギリス. 現CEOは Kabir Kumar Nath.
CMPS を有する IPO日 2020-09-18, 166 名の正社員, に上場 NASDAQ Global Select, 時価総額 $572.67M.
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
